Circulating tumor DNA identifies patients with diffuse large B-cell lymphoma who are at risk for disease recurrence, Dr. Mark J. Roschewski and associates at the National Cancer Institute, Bethesda, Md., reported in the Lancet.
A study of 126 patients who were examined over an average of 11 years showed that surveillance of circulating tumor DNA had a positive predictive value of 88.2% (95% confidence interval, 63.6-98.5) and a negative predictive value of 97.8% (95% CI, 92.2-99.7), and detected risk of recurrence at a median of 3.5 months before evidence of clinical disease, the authors said in the report.
The findings suggest that interim circulating tumor DNA is “a promising biomarker” for predicting risk of treatment failure, they wrote.
Read the full article here.
